Deadline: 01-Oct-2025
Pfizer has announced a Request for Proposals (RFP) for independent medical education (IME) projects focusing on maintenance therapy in HER2+ metastatic breast cancer (MBC) within the United States.
The focus is on the role of maintenance therapy in the 1L HER2+ MBC setting, including the current standard of care approach introduced by CLEOPATRA, maintenance therapy considerations with endocrine therapy for HR+/HER2+ MBC patients, combinations in the 1L HER2+ MBC maintenance setting including differentiation of therapy by HR status, overall treatment paradigm and evolving first-line standard of care options for patients with HER2+ MBC based on latest clinical data updates, safety profiles of available therapies and how they affect adverse event management including early identification and appropriate mitigation strategies, sequencing of available therapies, and re-treatment algorithms.
Organizations eligible to apply include US-based medical and allied health schools, hospitals and healthcare institutions, professional organizations, medical societies, and medical education companies. Only organizations, not individuals, may receive grants, and the requesting institution must be able to legally receive award funding directly from Pfizer.
Educational formats that will be considered range from conference symposia, grand rounds, peer-to-peer education, online courses, webinars, videos, podcasts, and newsletters. The target audience includes community medical oncologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in MBC care.
Grant requests may range from USD 10,000 to USD 250,000, with an estimated total budget of USD 500,000 for this RFP. The application deadline is October 1, 2025, with grant awards expected to be announced by October 31, 2025. Projects are anticipated to start in December 2025 and run through May 2027, with an approximate preferred length of 18 months.
For more information, visit Pfizer.
